GRCL - Gracell jumps 20% on long-term data for lymphoma candidate
2023-06-12 12:35:53 ET
Gracell Biotechnologies ( NASDAQ: GRCL ) added ~20% on Monday after the Chinese biotech announced long-term follow-up data for its CAR-T cell therapy GC012F in relapsed/refractory B-cell non-Hodgkin’s Lymphoma.
According to a presentation at the European Hematology Association (EHA2023) Congress on Saturday, GC012F, which targets both CD19 and B-cell maturation antigen (BCMA) in cancer cells, led to a 100% overall response rate (ORR) at three months.
The single-arm investigator-initiated trial involved nine r/r B-NHL patients, all of whom expressed CD19, and seven out of eight indicated BCMA. As of April 12, 2023, all had completed three months of follow-up with a median follow-up of 293 days.
Other highlights of the readout include 77.8% and 66.7% complete response rates at three months and six months, respectively.
As for safety, 56% of patients experienced Grade 1 cytokine release syndrome (CRS) and one patient experienced a Grade 3 CRS of two days.
More on Gracell
- Gracell stock surges ~30% on FDA nod to start trial of blood cancer drug
- Gracell spikes as H.C. Wainwright initiates with Buy on upcoming catalyst
For further details see:
Gracell jumps 20% on long-term data for lymphoma candidate